Chi Sheng Chemical Total Liabilities

Latest as of June 2025: NT$550.20 Million TWD ≈ $17.33 Million USD

Chi Sheng Chemical total liabilities. Based on the latest financial reports, Chi Sheng Chemical (4111) has total liabilities worth NT$550.20 Million TWD (≈ $17.33 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Chi Sheng Chemical fund operations to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Chi Sheng Chemical (2017–2024)

Total liabilities of Chi Sheng Chemical from 2017 to 2024. This chart illustrates how Chi Sheng Chemical's total liabilities have evolved over time, based on quarterly financial data.

Chi Sheng Chemical Competitors by Total Liabilities

The table below lists competitors of Chi Sheng Chemical ranked by their total liabilities.

Company Country Total Liabilities
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
Turkey TL191.45 Million
DYO Boya Fabrikalari Sanayi ve Ticaret AS
IS:DYOBY
Turkey TL11.92 Billion
UIL Co. Ltd
KQ:049520
Korea ₩83.92 Billion
Faraday Future Intelligent Electric Inc.
NASDAQ:FFAI
USA $270.10 Million
Credo Brands Marketing Limited
NSE:MUFTI
India Rs3.63 Billion
Aplisens SA
WAR:APN
Poland zł12.46 Million
Munjal Showa Limited
NSE:MUNJALSHOW
India Rs1.87 Billion
Bekasi Fajar Industrial Estate
JK:BEST
Indonesia Rp1.29 Trillion

Liability Composition Analysis (2017–2024)

This chart breaks down Chi Sheng Chemical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Chi Sheng Chemical.

Liquidity & Leverage Metrics

Chi Sheng Chemical Total Liabilities Ratios Explained

Chi Sheng Chemical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.84 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Chi Sheng Chemical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Chi Sheng Chemical (2017–2024)

The table below shows the annual total liabilities of Chi Sheng Chemical from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 NT$475.08 Million
≈ $14.97 Million
-13.15%
2023-12-31 NT$547.04 Million
≈ $17.23 Million
-5.42%
2022-12-31 NT$578.38 Million
≈ $18.22 Million
+3.46%
2021-12-31 NT$559.04 Million
≈ $17.61 Million
+36.04%
2020-12-31 NT$410.93 Million
≈ $12.95 Million
-8.73%
2019-12-31 NT$450.25 Million
≈ $14.19 Million
-1.74%
2018-12-31 NT$458.24 Million
≈ $14.44 Million
+6.97%
2017-12-31 NT$428.39 Million
≈ $13.50 Million
--

About Chi Sheng Chemical

TWO:4111 Taiwan Medical Instruments & Supplies
Market Cap
$53.72 Million
NT$1.71 Billion TWD
Market Cap Rank
#21435 Global
#1318 in Taiwan
Share Price
NT$28.50
Change (1 day)
-0.35%
52-Week Range
NT$28.50 - NT$30.75
All Time High
NT$36.05
About

Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic … Read more